Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002024760 | SCV002309550 | likely pathogenic | Amyloidosis, hereditary systemic 1 | 2021-08-04 | criteria provided, single submitter | clinical testing | This variant has been observed in individual(s) with TTR-related conditions (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with alanine at codon 74 of the TTR protein (p.Glu74Ala). The glutamic acid residue is highly conserved and there is a moderate physicochemical difference between glutamic acid and alanine. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TTR protein function. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Glu74 amino acid residue in TTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12101461, 25471118, 27238058, 16053476). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. |